Articles Service
Original Article
Cobas Pure Integrated Solutions에서의 Tacrolimus 전기화학발광 면역측정법의 성능평가
Performance of Tacrolimus Electrochemiluminescence Immunoassay on Cobas Pure Integrated Solutions
삼광의료재단1, Human Genome Sequencing Center, Baylor College of Medicine2, 울산대학교 의과대학 서울아산병원 진단검사의학과3
Samkwang Medical Laboratories1, Seoul, Korea; Human Genome Sequencing Center2, Baylor College of Medicine, Houston, Texas, USA; Department of Laboratory Medicine3, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Correspondence to:This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Lab Med Online 2024; 14(3): 224-229
Published July 1, 2024 https://doi.org/10.47429/lmo.2024.14.3.224
Copyright © The Korean Society for Laboratory Medicine.
Abstract
방법: Tacrolimus 정도관리물질 및 복용 중인 환자의 잔여 전혈 검체를 Cobas Pure에서의 tacrolimus ECLIA 평가에 사용하였다. 평가는 Clinical and Laboratory Standards Institute (CLSI) EP5-A3에 따른 정밀도, CLSI EP6-A에 따른 직선성, CLSI EP9-A3에 따른 방법간 비교 및 carryover를 포함하였다. 방법 간 비교는 Cobas Pure에서의 tacrolimus ECLIA 결과를 tacrolimus ACMIA (Siemens Healthineers, USA)와 LC-MS/MS (Waters Corporation, USA) 결과와 비교하였다.
결과: 검사실 내 정밀도는 저, 중, 고농도에서 각각 4.0%, 3.1%, 3.2%였고, 0.91 ng/mL – 27.43 ng/mL 범위 내에서 직선성을 보였다. Cobas Pure의 tacrolimus ECLIA 측정결과는 ACMIA와는 0.977, LC-MS/MS와는 0.994의 상관계수를 보였으나 약간의 차이를 보였다. Carryover 효과는 0.03%였다.
결론: Cobas Pure platform에서의 tacrolimus ECLIA 수행능 평가 결과, 허용 가능한 정밀도, 직선성 및 타 검사법과의 상관성을 보였으나 약간의 차이를 보였다. 따라서 본 연구 결과 임상 검사실에서의 tacrolimus 치료적 모니터링에 사용하기 적합할 것으로 판단된다.
Methods: Quality control materials and residual whole blood samples from patients receiving tacrolimus were used in evaluating the performance metrics, including the precision, linearity, comparison, and carryover, of tacrolimus ECLIA (Roche Diagnostics GmbH, Germany) on cobas pure. The precision, linearity, and comparison were assessed in accordance with Clinical and Laboratory Standards Institute guidelines EP5-A3, EP6-A, and EP9-A3, respectively, and the carryover was calculated. Results of tacrolimus ECLIA on cobas pure were compared with those of tacrolimus ACMIA (Siemens Healthineers, USA) and LC-MS/MS (Waters Corporation, USA) on other platforms.
Results: The within-laboratory precisions of tacrolimus ECLIA on cobas pure were 4.0%, 3.1%, and 3.2% at low, medium, and high concentrations of quality control materials. The linearity of the assay was acceptable (0.91–27.43 ng/mL). Correlation analysis indicated that the results of tacrolimus ECLIA on cobas pure were comparable to those of Dimension TAC and LC-MS/MS (r=0.977 and 0.994, respectively) with slight difference. Moreover, the carryover effect was 0.03%.
Conclusions: Tacrolimus ECLIA on cobas pure showed acceptable precision, linearity, and correlation with ACMIA and LC-MS/MS except for a slight difference. The overall performance of tacrolimus ECLIA on cobas pure is suitable for the therapeutic drug monitoring of tacrolimus in clinical laboratories.
Keywords
INTRODUCTION
Tacrolimus is a calcineurin inhibitor immunosuppressive agent discovered in 1984 [1]. Since its discovery, tacrolimus has been widely prescribed for organ transplant recipients and other patients in need of immunosuppression. However, this drug has a relatively narrow therapeutic index and concentration-related side effects [2]. Tacrolimus at inappropriate levels may cause nephrotoxicity, neurotoxicity, and diabetogenicity [2] or increase the risk of infection due to over-immunosuppression. Conversely, insufficient concentration of tacrolimus increases the risk of allograft rejection [3]. Careful monitoring of tacrolimus concentration in transplant recipients is essential to prevent side effects and graft rejection.
Tacrolimus concentration is measured using various methods, including liquid chromatography-tandem mass spectrometry (LC-MS/MS) and immunoassay [4]. Tacrolimus measurement values may differ depending on the test method and pre-treatment employed. Although the reference measurement method for tacrolimus is based on isotope dilution LC-MS/MS [5], immunoassays for tacrolimus are often used in clinical laboratories because they offer the advantage of automation through the use of modular analyzers.
Previous multicenter studies evaluated the performance of tacrolimus electrochemiluminescence immunoassay (ECLIA) [6]. However, the launch of a new diagnostic platform requires additional validation, including comparison with existing measurement procedures. Cobas pure integrated solutions (Roche Diagnostics International AG, Rotkreuz, Switzerland) is a new modular diagnostic system combining clinical chemistry, immunoassay, and ion-selective electrode (ISE) diagnostic testing. In the present study, we evaluated the analytical performance of tacrolimus ECLIA on cobas pure platform and compared it with that of LC-MS/MS and affinity chrome-mediated immunoassay (ACMIA).
MATERIALS AND METHODS
This study was waived from deliberation by the Institutional Review Board of Asan Medical Center (S2020-1899).
1. Laboratory measurements
Before measurement, pretreatment including cell lysis, tacrolimus extraction, and precipitation of blood protein was conducted using Elecsys ISD sample pretreatment reagent (Roche Diagnostics GmbH, Mannheim, Germany). The pretreated samples were centrifuged, and the supernatants containing tacrolimus were assayed. Blood tacrolimus concentrations were measured using Elecsys Tacrolimus assay (Roche Diagnostics GmbH), which is based on the principle of ECLIA, and cobas pure integrated solutions (Roche Diagnostics International Ltd., Rotkreuz, Switzerland) in accordance with the manufacturer’s instructions. For comparison, Dimension TAC Flex assay (Siemens Healthineers, Tarrytown, NY, USA), which is based on the principle of affinity chrome-mediated immunoassay (ACMIA), was conducted on a Dimension ExL 200 analyzer (Siemens Healthineers). LC-MS/MS was performed on an ACQUITY UPLC®zHSS SB C18, 2.1 mm×30 mm, 1.8 fim and Xevo TQ-S spectrometer (Waters Corporation, Milford, MA, USA).
2. Precision
The assay precision was evaluated in accordance with the Clinical and Laboratory Standards Institute (CLSI) guideline EP5-A3 [7]. Quality control (QC) materials (PreciControl ISD, Roche Diagnostics GmbH) at low, medium, and high concentrations were used. Two replicates of each QC sample were analyzed twice a day for 20 days. The acceptance criterion for precision was less than 6% analytical coefficient of variation (CV), as recommended by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee (IATDMCT) [8].
3. Linearity
Linearity was evaluated in accordance with CLSI guideline EP6-A [9]. Patient samples of high (27.43 ng/mL) and low (0.91 ng/mL) tacrolimus concentrations were diluted to produce five equally spaced concentrations. Samples at each concentration were measured in four replicates. The means of the measured values of each concentration were compared with assigned values.
4. Comparison
Method comparison was performed in accordance with CLSI guideline EP9-A3 [10]. In January 2021, we collected residual whole blood samples from patients receiving tacrolimus. Values measured using Elecsys Tacrolimus assay on cobas pure integrated solutions, Dimension TAC Flex assay on a Dimension ExL 200 analyzer, and LC-MS/MS on a Xevo TQ-S spectrometer were compared. Eight samples per day were measured on each measurement system.
5. Sample carryover
Samples of high and low concentrations were prepared for carryover evaluation. After measuring high-concentration samples four times (H1, H2, H3, and H4) consecutively, low-concentration samples (L1, L2, L3, and L4) were measured four times consecutively. The carryover between samples (%) was calculated according to the following equation:
{L1−(L3 + L4)/2}/{(H3+H2)/2−(L3+L4)/2}×100. [11, 12]
6. Statistical analysis
Statistical analysis was conducted using Microsoft Excel (Microsoft Corp., Redmond, WA, USA), EP Evaluator Release 12 software (David G. Rhoads Associates, Kennett Square, PA, USA), and GraphPad Prism version 9 for Windows (GraphPad Software, San Diego, CA, USA).
RESULTS
1. Precision
The results of the assay precision are shown in Table 1. The total CVs of the QC materials at low, medium, and high concentrations were 4.0%, 3.1%, and 3.2%, respectively, which were higher than the within-run CVs of 1.9%, 1.0%, and 1.0%, respectively.
-
Table 1 Precision of Elecsys Tacrolimus assay on cobas pure integrated solutions
Level Mean (ng/mL) Within-run imprecision Total imprecision SD (ng/mL) CV (%) SD (ng/mL) CV (%) Low 2.89 0.06 1.9 0.11 4.0 Middle 10.51 0.10 1.0 0.33 3.1 High 18.70 0.18 1.0 0.60 3.2 Abbreviations: SD, standard deviation; CV, coefficient of variation.
(Conversion factors: ng/mL ×1.2438=nmol/L).
2. Linearity
The results of linearity evaluation are shown in Fig. 1. The linear range, showing a coefficient of determination (R2) greater than 0.99, was 0.91–27.43 ng/mL (Conversion factors: ng/mL×1.2438=nmol/L). The linearity error % was 2.6% when the assigned value and the values from the linear fit were compared. The linearity regression slope and intercept were as follows:
-
Figure 1. Linearity of the Elecsys Tacrolimus assay on Cobas Pure integrated solutions. (A) Scatter plot, (B) residual plot. (Conversion factors: ng/mL ×1.2438=nmol/L).
Y (observed)=1.014x (expected)–0.0267
3. Comparison
A total of 80 samples ranging from 1.33 ng/mL to 27.63 ng/mL were analyzed for method comparison. Among the 80 patients, 35 received kidney transplantation, 30 liver transplantation, 13 lung transplantation, and 2 heart transplantation. The results of comparisons between the Elecsys Tacrolimus assay on cobas pure, Dimension TAC Flex assay on Dimension ExL 200 analyzer, and LC-MS/MS on Xevo TQ-S spectrometer are shown in Fig. 2. The results obtained using cobas pure were significantly correlated with those obtained using Dimension TAC Flex and LC-MS/MS (R=0.9771 and R=0.9941, respectively). Tacrolimus levels measured by the cobas pure method showed positive mean differences compared to those measured by the Dimension TAC Flex and LC-MS/MS methods, 1.55 and 1.42 ng/mL, respectively, as demonstrated by Bland-Altman plots.
-
Figure 2. Scatter plots and Bland-Altman plots between Elecsys Tacrolimus assay on Cobas Pure and different tacrolimus assays. (A) Comparison between Elecsys Tacrolimus assay on Cobas pure and LC-MS/MS on Xevo TQ-S spectrometer. (B) Comparison between Elecsys Tacrolimus assay and Dimension TAC Flex assay on Dimension ExL 200. In the scatter plots, the dotted line represents 1:1 line and the red line represents Deming regression. In the Bland-Altman plots, the dotted line represents the mean bias. (Conversion factors: ng/mL ×1.2438=nmol/L).
4. Sample carryover
Four samples of high concentrations (18.4, 18.1, 18.2, and 18.2 ng/mL, respectively) and four samples of low concentrations (2.83, 2.82, 2.81, and 2.84 ng/mL, respectively) were analyzed for sample carryover evaluation. The carryover between samples was acceptable below 1.0% and was 0.03%.
DISCUSSION
In terms of precision, we observed within-run CVs between 1.0% and 1.9%, and total CVs between 3.1% and 4.0%, depending on the concentrations of the QC materials. Within-run CVs of 2.0–4.5% and total CVs of 2.7–8.1% were observed in previous multicenter studies that evaluated Elecsys Tacrolimus assay [6, 13]. In addition, Dimension TAC Flex, another immunoassay used for comparison, showed a total CV of 5.7–7.3% in a previous evaluation study [14]. The results of the present study on the tacrolimus measurement of cobas pure showed a similar or better precision than those of previous studies. In 2016, an assay precision performance of less than 6% analytical CV was presented by IATDMCT as a goal in the case of immunosuppressive drugs [8]. In this manner, Elecsys Tacrolimus assay on cobas pure was deemed sufficient for clinical implementation. The linearity and sample carryover of the assay were also acceptable.
Comparison with LC-MS/MS and ACMIA also showed acceptable correlation coefficient values of R>0.975. However, compared with LC-MS/MS and ACMIA, tacrolimus ECLIA on cobas pure showed average bias values of 1.42 and 1.55 ng/mL, respectively, indicating a slightly higher value of tacrolimus. A previous study that evaluated the same tacrolimus ECLIA on other platforms also observed an average of 4.4% positive bias compared with LC-MS/MS [13]. Immunoassay results can be affected by various factors, such as matrix effect [15], different calibration [16], non-specific binding [17], cross-reactivity, and autoantibodies and heterophile antibodies [18-20]. Additionally, tacrolimus is extracted from whole blood samples, thus it is influenced by the whole blood extraction method and post-extraction stability [21, 22]. Furthermore, tacrolimus undergoes extensive metabolism in the body and exists as various types of metabolites [23], and different tacrolimus metabolites can be sources of cross-reactivity. Using different calibrators from different manufacturers can also affect tacrolimus measurements. With the availability of certified reference materials (CRMs), using calibrators with assigned values traceable to higher CRMs can be helpful for tacrolimus standardization [24]. Further efforts are needed to standardize tacrolimus assays and reduce the inter-assay variations in tacrolimus measurement.
Cobas pure is a novel modular automatic analyzer developed for use in limited spaces, such as small- and medium-sized laboratories or satellite laboratories. Combining clinical chemistry, ISE, and immunoassay modules, this analyzer can be used to test a large number of analytes. Although we did not evaluate all the analytes available on cobas pure in this study, we observed no significant difference between the results of tacrolimus assay and those of Dimension TAC assay and LC-MS/MS conducted on other platforms.
In conclusion, the performance of tacrolimus ECLIA on cobas pure integrated solutions was acceptable. Until now, tacrolimus concentrations vary according to the measurement method, especially among immunoassays. Improving the reliability of measurements of immunosuppressants, including tacrolimus, is crucial to improve the prognosis of organ transplant recipients.
Conflicts of Interest
None declared.
References
- Hatanaka H, Iwami M, Kino T, Goto T, Okuhara M. FR-900520 and FR-900523, novel immunosuppressants isolated from a Streptomyces. I. Taxonomy of the producing strain. J Antibiot (Tokyo) 1988;41:1586-91.
- Laskow DA, Neylan JF 3rd, Shapiro RS, Pirsch JD, Vergne-Marini PJ, Tomlanovich SJ. The role of tacrolimus in adult kidney transplantation: a review. Clin Transplant 1998;12:489-503.
- Oellerich M, Armstrong VW, Schütz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem 1998;31:309-16.
- Kalt DA. Tacrolimus: a review of laboratory detection methods and indications for use. Lab Med 2017;48:e62-5.
- Taibon J, van Rooij M, Schmid R, Singh N, Albrecht E, Anne Wright J, et al. An isotope dilution LC-MS/MS based candidate reference method for the quantification of cyclosporine A, tacrolimus, sirolimus and everolimus in human whole blood. Clin Biochem 2020;82:73-84.
- Qin X, Rui J, Xia Y, Mu H, Song SH, Raja Aziddin RE, et al. Multi-center performance evaluations of tacrolimus and cyclosporine electrochemiluminescence immunoassays in the Asia-Pacific region. Ann Lab Med 2018;38:85-94.
- Clinical, Laboratory Standards Institute. Evaluation of precision of quantitative measurement procedures; Approved guideline—Third edition. CLSI document EP05-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2014.
- Seger C, Shipkova M, Christians U, Billaud EM, Wang P, Holt DW, et al. Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. Ther Drug Monit 2016;38:170-89.
- Clinical, Laboratory Standards Institute. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; Approved guideline. CLSI document EP06-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2003.
- Clinical, Laboratory Standards Institute. Measurement procedure comparison and bias estimation using patient samples; Approved guideline—Third edition. CLSI document EP09-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2013.
- Broughton PM. Carry-over in automatic analysers. J Automat Chem 1984;6:94-5.
- Lee EJ, Kim HK, Ahn S, Lee W, Kim HS, Chun S, et al. Accuracy evaluation of automated electrochemiluminescence immunoassay for everolimus and sirolimus compared to liquid chromatography-tandem mass spectrometry. J Clin Lab Anal 2019;33:e22941.
- Shipkova M, Vogeser M, Ramos PA, Verstraete AG, Orth M, Schneider C, et al. Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. Clin Biochem 2014;47:1069-77.
- Cho EJ, Ko DH, Lee W, Chun S, Lee HK, Min WK. Performance of the Dimension TAC assay and comparison of multiple platforms for the measurement of tacrolimus. J Clin Lab Anal 2018;32:e22357.
- Wood WG. “Matrix effects” in immunoassays. Scand J Clin Lab Invest Suppl 1991;205:105-12.
- Whicher JT. Calibration is the key to immunoassay but the ideal calibrator is unattainable. Scand J Clin Lab Invest Suppl 1991;205:21-32.
- Güven E, Duus K, Lydolph MC, Jørgensen CS, Laursen I, Houen G. Non-specific binding in solid phase immunoassays for autoantibodies correlates with inflammation markers. J Immunol Methods 2014;403:26-36.
- Tate J, Ward G. Interferences in immunoassay. Clin Biochem Rev 2004;25:105-20.
- Hermida J, Tutor JC. Falsely increased blood tacrolimus concentrations using the ACMIA assay due to circulating endogenous antibodies in a liver transplant recipient: a tentative approach to obtaining reliable results. Ther Drug Monit 2009;31:269-72.
- Rostaing L, Cointault O, Marquet P, Josse AG, Lavit M, Saint-Marcoux F, et al. Falsely elevated whole-blood tacrolimus concentrations in a kidney-transplant patient: potential hazards. Transpl Int 2010;23:227-30.
- Kim H, Park H, Lee S, Chae H, Song SH, Lee Y, et al. Immunosuppressive drug measurement by liquid chromatography coupled to tandem mass spectrometry: interlaboratory comparison in the Korean clinical laboratories. Ann Lab Med 2021;41:268-76.
- Gant Kanegusuku A, Yeo KJ. Is the automated Elecsys tacrolimus assay on the Roche cobas e 602 analyzer an acceptable replacement for a liquid chromatography-tandem mass spectrometry-based assay?. Am J Clin Pathol 2024;161:97-106.
- Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007;22:328-35.
- Rigo-Bonnin R, Canalias F. Traceability of immunosuppressant’s mass concentration results obtained using different commercial calibrators. Clin Biochem 2019;63:113-20.